Samsung Biologics

207940.KO

693.83 USD

-4.97

-0.71%

Overview

Last close

693.83 usd

Market cap

32.12B usd

52 week high

761.21 usd

52 week low

634.23 usd

Target price

689.51 usd

Valuation

P/E

N/A

Forward P/E

78.7402

Price/Sales

17.7261

Price/Book Value

6.7501

Enterprise Value

56.18B usd

EV/Revenue

14.8005

EV/EBITDA

29.3749

Key financials

Revenue TTM

3.80B usd

Gross Profit TTM

2.12B usd

EBITDA TTM

1.85B usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

13.09B usd

Net debt

205.82M usd

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.